

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Tradesnark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPEICATION NO.	FILING DATE	FIRST NAMED INVENTOR !	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/982,965	12/02/1997	GEORGE H. LOWELL 5	359292000110	9909
; 26694 7	7590 05/21/2002	a er est		
VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP			EXAMINER	
P.O. BOX 34385 WASHINGTON, DC 20043-9998			BUDENS, ROBERT D	
:		•	ART UNIT	PAPER NUMBER
,		1	1648	
•		:	DATE MAILED: 05/21/2002	25

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and 1 amark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER FILING DATE FIRST NAMED APPLICANT ATTY, DOCKET NO.

EXAMINER

ART UNIT PAPER NUMBER

DATE MAILED:

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

M	Responsive to communication(s) filed on 2-27-02					
	This action is FINAL.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 D.C. 11; 453 Q.G. 213.					
the	hortened statutory period for response to this action is set to expire the land month(s), or thirty days, ichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 36(a).					
Dis	position of Claims					
	Claim(s)					
Apj	plication Papers					
	See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed onis/are objected to by the Examiner. The proposed drawing correction, filed onis approved disapproved. The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner.					
Pric	ority under 35 U.S.C. § 119					
	Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).					
	All Some* None of the CERTIFIED copies of the priority documents have been					
•	received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule 17.2(a)). Certified copies not received:					
	Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
Atta	achment(s)					
	Notice of Reference Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s)					
	Interview Summary, PTO-413					
	Notice of Draftperson's Patent Drawing Review, PTO-948					
	Notice of Informal Patent Application, PTO-152					
	SEE OFFICE ACTION ON TH FOLLOWING PAGES					

Serial No. 08/982,965 Art Unit 1648

10

15

20

25

The status of the related application(s) cited at the first page of the specification should be updated, if necessary, to ensure a properly completed file record.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Applicant's request for a Continuing Prosecution Application is acknowledged. Accordingly, **FINALITY** of the last Office Action is withdrawn.

The Examiner acknowledges Applicant's Request for a Continuing Prosecution Application, Paper No. 24, filed February 27, 2002, requesting entry of the Amendment After Final Rejection, Paper No. 21, filed September 27, 2001. In view of Applicant's Request, the status of the claims is as follows: Claim 5 has been canceled; Claims 1-4, 6-9 and newly added claims 10-11 (claims 9-10 in Paper No. 21 renumbered in accordance with 37 CFR § 1.126) are currently pending before the Examiner.

The Examiner acknowledges Applicant's submission of a new Oath and Declaration, attachment to Paper No. 24, filed February 27, 2002. The newly submitted Oath and Declaration is acceptable.

Claims 7 and newly added claims 10-11 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 7 is vague and indefinite in the recitation "ratio range is 1:1" since there is no range in claim 7. Amendment of claim 7 to delete "range" would obviate this rejection. Claim 10 is vague and indefinite in the recitation "mixing gp 160 and proteosomes, combining gp 160 and proteosomes" since it is unclear whether these are two distinct steps in one method or two different methods encompassed within the

Serial No. 08/982,965 Art Unit 1648

5

10

15

20

25

30

same claim. Amendment of claim 10 to more clearly point out and define what is encompassed by the language "mixing" and "combining" would obviate this rejection.

Upon review of Applicant's parent application, 07/065,440, Applicant <u>IS NOT</u> accorded benefit of the filing date of the earlier filed application. The specification of application Serial No. 07/065,440 does not provide support for gp160-proteosome complexes as presently claimed.

Claims 1-4, 6-9 and newly added claims 10-11 remain rejected under 35 U.S.C. § 103 as being unpatentable over Lowell et al. (U) or Lowell et al. (V) or Smith et al. (W) or Avraham et al. (X) in view of Ratner et al. (Y) for the reasons of record set forth in the last Office Action. Applicant's arguments have been fully considered but are not deemed persuasive to overcome the rejection. Applicant arguments refer to the exemplified recombinant "R32ft" and the presence of specific adjuvants such as alum and discusses the trimeric complexes of gp 160. However, Applicant's arguments are directed to limitations not found in the claimed invention. Applicant's claims are quite broad with respect to the ratios of proteins and proteosomes, to the type of adjuvant and to the desired effect of inducing antibody formation. As stated in the previous rejections, it would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to produce proteosome-gp 160 complexes and use them for inducing antibodies for the reasons of record. Even newly added claims 10-11 only add further limitations that the complexes are lyophilized or dialyzed, both very well known techniques in protein purification and storage. Should Applicant desire to rely on the limitations set forth in Applicant's Response, Applicant should amend the claims to reflect those limitations. In the absence of convincing objective evidence to the contrary, the rejection is deemed proper and is maintained.

Serial No. 08/982,965 Art Unit 1648

No claim is allowed.

Papers relating to this application may be submitted to Group 1600 by facsimile transmission. The Fax number is (703) 308-4242. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Robert D. Budens at (703) 308-2960. The Examiner can normally be reached Monday-Thursday from 6:30 AM-4:00 PM, (EST). The Examiner can also be reached on alternate Fridays. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, James Housel, can be reached at (703) 308-4027.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist at (703) 308-0196.

Robert D. Budens Primary Examiner Art Unit 1648

20 rdb May 20, 2002

5

10

15